Improvement of Suspected Linear Morphea seen with Topical Ruxolitinib
Main Article Content
Keywords
Linear morphea, ruxolitinib cream
Abstract
Linear morphea is an autoimmune skin condition characterized by localized sclerosis and discoloration. Current standard of care includes topical and intralesional steroids, phototherapy, and immunosuppressive agents; however, no gold-standard treatment exists. We present a 34-year-old female who presented with a hypopigmented and indurated plaque in an en coup de sabre configuration on her forehead, suspicious of linear morphea, that improved significantly in thickness and hypopigmentation after eight weeks of 1.5% ruxolitinib cream.
References
2. Diagnostic criteria, severity classification and guidelines of localized scleroderma - Asano - 2018 - The Journal of Dermatology - Wiley Online Library. Accessed August 13, 2023. https://onlinelibrary.wiley.com/doi/full/10.1111/1346-8138.14161
3. Szczęch J, Samotij D, Jaworecka K, Tobiasz A, Reich A. Quality of Life in Patients with Morphea: A Cross-Sectional Study and a Review of the Current Literature. Biomed Res Int. 2020;2020:9186274. doi:10.1155/2020/9186274
4. Penmetsa GK, Sapra A. Morphea. In: StatPearls. StatPearls Publishing; 2023. Accessed August 13, 2023. http://www.ncbi.nlm.nih.gov/books/NBK559010/
5. Ulc E, Rudnicka L, Waśkiel-Burnat A, Warszawik-Hendzel O, Niemczyk A, Olszewska M. Therapeutic and Reconstructive Management Options in Scleroderma (Morphea) en Coup de Sabre in Children and Adults. A Systematic Literature Review. J Clin Med. 2021;10(19):4517. doi:10.3390/jcm10194517
6. Wenzel D, Haddadi NS, Afshari K, Richmond JM, Rashighi M. Upcoming treatments for morphea. Immunity, Inflammation and Disease. 2021;9(4):1101-1145. doi:10.1002/iid3.475
7. Pedroza M, To S, Assassi S, Wu M, Tweardy D, Agarwal SK. Role of STAT3 in skin fibrosis and transforming growth factor beta signalling. Rheumatology (Oxford). 2018;57(10):1838-1850. doi:10.1093/rheumatology/kex347
8. Sheikh A, Rafique W, Owais R, Malik F, Ali E. FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology. Ann Med Surg (Lond). 2022;81:104499. doi:10.1016/j.amsu.2022.104499
9. Papara C, De Luca DA, Bieber K, Vorobyev A, Ludwig RJ. Morphea: The 2023 update. Front Med (Lausanne). 2023;10:1108623. doi:10.3389/fmed.2023.1108623
10. Mertens JS, Seyger MMB, Thurlings RM, Radstake TRDJ, de Jong EMGJ. Morphea and Eosinophilic Fasciitis: An Update. Am J Clin Dermatol. 2017;18(4):491-512. doi:10.1007/s40257-017-0269-x
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.